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OBJECTIVES: Ticagrelor is a reversibly binding oral P2Y12-receptor antagonist de-
veloped for reduction of thrombosis. The PLATO trial compared ticagreloraspirin
to clopidogrelaspirin in individuals with acute coronary syndromes (ACS); ti-
cagrelor was superior on the primary composite endpoint of cardiovascular death,
myocardial infarction (MI) or stroke, without an increase in major bleeding events.
The current study estimates the lifetime cost-effectiveness of ticagrelor relative to
generic clopidogrel fromaSingapore public health care perspective.METHODS: For
the analysis of cost-effectiveness, a two-part cost-effectiveness model was used.
The first part was a 12-month decision tree using PLATO trial data to estimate rates
ofmajor cardiovascular events, health care costs, and health-related quality of life.
The second part was a Markovmodel estimating lifetime quality-adjusted survival
and costs conditional on whether a non-fatal MI, a non-fatal stroke, or no MI or
stroke occurred during the initial 12 months. The model applied a lifetime horizon
to calculate mean direct medical costs and QALYs. The results are presented as
incremental cost-effectiveness ratios (ICER’s). Daily costs of SGD1.10 for generic
clopidogrel and SGD6.00 for ticagrelorwere applied.We calculated short term costs
by applying Singapore unit costs, and costs from a comparable Asian country (Ko-
rea) to derive the Markov costs. Probabilistic sensitivity analysis was performed.
RESULTS: Ticagrelor was associated with a lifetime QALY gain of 0.13, primarily
driven by lower cardiovascular mortality. The resulting incremental cost per QALY
gained was SGD10,136 from the public sector perspective. Probabilistic sensitivity
analysis indicated that ticagrelor had more than 99% probability of being cost-
effective given the recommended WHO willingness to pay threshold of one GDP/
capita or SGD56,000 per QALY. CONCLUSIONS: Based on the PLATO trial data, one
year treatment with ticagreloraspirin versus generic clopidogrelaspirin in ACS
patients, relative to WHO reference standards, is cost-effective from a Singapore
public health care perspective.
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OBJECTIVES:To estimate the long-time cost-effectiveness of Left Atrial Appendage
(LAA) occlusion device for preventing stroke in a hypothetical cohort of 65-year-old
patientswith atrial fibrillation (AF).METHODS:Adecision analyticmodel was used
to perform a cost-effectiveness analysis comparing LAA occlusion device and 5
alternative anticoagulant therapies from a health care provider perspective. Treat-
ment strategies for AF are included Aspirin, dual therapy with Aspirin and Clopi-
dogrel, Warfarin, Dabigatran 150mg or 110mg, and LAA occlusion device. The pa-
rameters including rate of adverse events, utility, and costs were derived from the
ACTIVE trial, RE-LY trial, PROTECT trial, and published references in our model.
Outcomes are quality-adjusted life years (QALYs), lifetime costs, and incremental
cost-effectiveness ratios (ICERs). Costs and QALYs were discounted at an annual
rate of 3%. One way sensitivity varied by the CHADS2score and probabilistic sen-
sitivity analyses (PSAs)were conducted to assess parameter uncertainty. RESULTS:
Compared with Aspirin, LAA occlusion device, Warfarin, Dabigatran 150mg and
110mg were cost-effective. The ICERs were US$975 per QALY with LAA occlusion
device, US$4,982 per QALY with Warfarin, US $10,672 per QALY with Dabigatran
150mg, US$10,972 per QALY with Dabigatran 110mg. When using Warfarin as a
comparator, LAA occlusion device is less costly and more effective, Dabigatran
150mg cost US$28,556 per QALY, and Dabigatran 110mg cost UD$37,328 per QALY.
For patient with CHADS2 score of 0, 1, 2, 3, or 3a4, the ICREs of LAA occlusion device
over Aspirin were US$1,257 per QALY, US$1,104 per QALY, US$894 per QALY,
US$626 per QALY, US$518 per QALY, respectively. LAA occlusion device was cost-
effective over 95% of theMonte Carlo simulation using a cost-effectiveness thresh-
old of US$50,000 per QALY.CONCLUSIONS:The LAA occlusion device is considered
cost-effective compared with Aspirin, Warfarin, Dabigatran 150mg or 110mg in AF
patients.
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OBJECTIVES: To estimate the cost-effectiveness of delayed troponin testing for
myocardial infarction (MI), as recommended in current guidelines, compared to
troponin testing and other biomarkers at presentation.METHODS:Wedeveloped a
decision analytic model to estimate the cost-effectiveness of diagnostic strategies
for MI, measured as the incremental cost per quality-adjusted life year (QALY)
gained by each strategy compared to the nextmost effective alternative. Themodel
was applied to a hypothetical population of 1000 patients attending hospital with
symptoms suggesting MI but a normal or non-diagnostic electrocardiogram (ECG)
and no major co-morbidities requiring hospital treatment. Sensitivity and speci-
ficity of the strategieswere estimated bymeta-analysis of diagnostic cohort studies
of presentation troponin T. The risk of reinfarction and death (with and without
treatment) was determined using data from a study by Mills et al, Lifetime QALYs
were estimated from life expectancy and corresponding annual utilities. The dis-
counted life expectancy of patientswithMI andMIwith reinfarctionwas estimated
from Polanczyk et al, while the utility of patients withMIwas estimated fromWard
et al. RESULTS: In all scenarios tested presentation high sensitivity troponin test-
ing was the most effective strategy with an incremental cost-effectiveness ratio
(ICER) below the £20,000/QALY threshold. Delayed troponin testing was only likely
to be cost-effective if a discharge decision could be made as soon as a negative
result was available and the £30,000/QALY threshold was used. CONCLUSIONS:
Delayed troponin testing is unlikely to be cost-effective compared to high sensitiv-
ity troponin testing at presentation in most scenarios. Current guidelines recom-
mending 10-12 hour troponin testing does not appear to promote cost-effective use
of hospital resources, unless services are in place to allow rapid decision making
once delayed test results are available.
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OBJECTIVES: The PLATO trial showed that ticagrelor significantly reduced the rate
of cardiovascular mortality, myocardial infarction, or stroke compared to clopi-
dogrel in patients with acute coronary syndrome (ACS) with additional drug cost.
Critical appraisal is necessarily important to justify adopting this new treatment in
the era of limited health care resources. This study aimed to evaluate long-term
cost-effectiveness of ticagrelor plus acetylsalicylic acid (ASA) versus clopidogrel
plus ASA in ACS patients in Thailand. METHODS: A two-part decision-analytic
model, comprising a one-year decision tree and a long-term Markov model, was
constructed to estimate lifetime costs and quality-adjusted life years (QALYs) from
Thai health care payer’s perspective. For the first year, data from PLATOwere used
to estimate rate of cardiovascular events, resource use, and QALYs. For year two
and onwards, clinical effectivenesswas estimated conditional on individual health
states occurred during the first year. Unit costs were based on Thai database. All
costs presented in year 2011 and effects were discounted at 3% per annum. A series
of sensitivity analyses were performed to assess robustness of the model.
RESULTS: The incremental cost -effectiveness ratios (ICERs) with ticagrelor were
312,044 and 79,979 THB/QALY compared to generic and branded clopidogrel, re-
spectively. Probabilistic sensitivity analysis indicated that ticagrelor has high prob-
abilities of being cost effective compared to generic (85.0%) and branded clopi-
dogrel (99.9%) at a willingness to pay threshold of 3 times GDP/capita.
CONCLUSIONS: It might be appropriate to assert that ticagrelor is an economically
valuable treatment of ACS within the Thai context.
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Peripheral arterial disease (PAD) is a condition in which there is blockage or nar-
rowing of the arteries that carry blood to the peripheries. Themost common symp-
tom of PAD is intermittent claudication (IC), characterised by pain in the legs on
walking that is relieved with rest. Symptoms of IC can be managed with exercise
therapy and/or vasoactive drugs. OBJECTIVES: To assess the cost-effectiveness of
the vasoactive drugs cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol
nicotinate for IC due to PAD in adultswhose symptoms continue despite a period of
conservativemanagement.METHODS:AMarkov decisionmodel was developed to
assess the lifetime costs and benefits of each vasoactive drug compared with no
vasoactive drug andwith each other. Regression analysiswas undertaken tomodel
the relationship betweenmaximumwalking distance and utility based on patient-
level data from a trial of cilostazol to enable quality of life impacts to be estimated
for the other drugs under consideration. Resource use data were sourced from the
literature and a comprehensive sensitivity analysiswas undertaken.RESULTS:The
economic evaluation suggests that naftidrofuryl oxalate is more effective and less
costly than cilostazol and pentoxifylline and has an estimated cost per QALY
gained of around £6070 compared with no vasoactive drug. Whilst there is limited
effectiveness evidence associated with inositol nicotinate, threshold analysis sug-
gests that it is unlikely to be considered to be cost-effective due to its more expen-
sive acquisition cost.CONCLUSIONS:This is the first published cost-utility analysis
in this areawhich extrapolates data over a lifetime and uses effectiveness evidence
from a network meta-analysis. In contrast to previous guidelines recommending
cilostazol, this comprehensive analysis suggests that naftidrofuryl oxalate is the
only vasoactive drug for PAD which is likely to be cost-effective at a willingness to
pay threshold of £20,000 per QALY gained.
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OBJECTIVES: To evaluate the cost-effectiveness of apixaban versus enoxaparin in
the prevention of venous thromboembolism (VTE) after total hip replacement
(THR) and total knee replacement (TKR) from the perspective of the Korean health
care system.METHODS:Adecision treemodel was developed to simulate the costs
and outcomes of VTE prevention, and consisted of 3 phases- 1) prophylaxis phase;
2) post-prophylaxis phase (up to 90 days); and 3) long-termcomplications phase (up
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to 5years). In order to estimate the differences in costs and outcomes between
apixaban and enoxaparin, the analysis was designed to capture acute and recur-
rent VTE events, prophylaxis-related adverse events (bleeding events) and deaths
associated with VTE and adverse events. Transition probabilities were derived
from phase III clinical trials comparing apixabanwith enoxaparin, ADVANCE 2 (for
THR population) andADVANCE 3 (for TKR population). Costswere derived from the
Korean Health Insurance Review and Assessment service. Utilities were derived
from published literature. The model reported effectiveness outcomes in quality-
adjusted life years (QALYs) and costs in Korean Won (KRW). One-way sensitivity
analyses were performed on assumptive parameters. RESULTS: For patients un-
dergoing TKR, apixaban dominated enoxaparin, that is apixaban provided more
benefit than enoxaparin as measured by increased quality-adjusted life years
(QALYs gained; 0.00239) andwith less costly (savings of KRW 23,124) per patient. In
case of patients undergoing THR, apixaban demonstrated an increase in quality-
adjusted life years (QALYs gained; 0.00467) with higher cost of KRW 5,343, which
translated into incremental cost-effectiveness ratio (ICER) of KRW 1,145,357 com-
paring apixaban with enoxaparin. The ICER was far below the willingness-to-pay
threshold in Korea (Per capita GDP). The sensitivity analyses showed that the re-
sults were robust across all input parameters. CONCLUSIONS: The results from the
model suggest that apixaban is a cost-effective alternative to enoxaparin for VTE
prophylaxis in patients undergoing both THR and TKR in Korea.
CARDIOVASCULAR DISORDERS – Patient-Reported Outcomes & Patient
Preference Studies
PCV32
A NON-CLINICAL RANDOMIZED CONTROLLED TRIAL ASSESSING IMPACT OF
PHARMACISTS LED INTERVENTION PROGRAMME FOR ENHANCING
MEDICATION ADHERENCE AND HEALTH-RELATED QUALITY OF LIFE
Saleem F1, Hassali MA1, Shafie AA1, Aljadhey H2, Haq N1, Atif M3
1Universiti Sains Malaysia, Penang, Malaysia, 2King Saud University, Riyadh, Riyadh, Saudi
Arabia, 3Allianze University College of Medical Sciences (AUCMS), Penang, Malaysia
OBJECTIVES: To evaluatewhether a pharmaceutical care intervention can result in
better understanding about hypertension, an increase in medication adherence to
antihypertensive therapy and an improvement of overall health-related quality of
life (HRQoL). METHODS: A randomized control trial was conducted whereby par-
ticipants received an educational intervention through hospital pharmacists who
provided them with information about hypertension treatment and management
and the importance of medication adherence. Hypertension knowledge, medica-
tion adherence and HRQoL were measured by means of self-administered ques-
tionnaires. Descriptive statistics were used to describe the demographic and dis-
ease characteristics of the patients. Inferential statistics (Chi square test, Mann-
Whitney U test andWilcoxon signed rank test) were used for inter- and intra-group
comparison respectively. SPSS 17was used for data analysis. RESULTS: Three hun-
dred eighty-five hypertensive patients were randomly assigned to the study [192 in
the control group (CG) and 193 in the intervention group (IG)]. No significant differ-
ences were observed in either group for mean age, gender, income, locality, edu-
cation, occupation and duration of disease. There was, however, a significant in-
crease in the participants’ levels of knowledge about hypertension (10.261.11,
P0.001) and medication adherence (3.240.93, P0.001) among the IG after the
completion of the intervention. Significant association was also reported in the
intra-IG group comparison (P0.001). A significant decrease in overall HRQoL in the
IG [(39.6930.25, P0.001), inter- and intra-group comparison] was observed after
the completion of the intervention programme. CONCLUSIONS: The pharmacist-
led intervention led to a significant increase in the participants’ levels of knowl-
edge about hypertension and a positive impact on medication adherence. There-
fore, the role of pharmacists in patient education must be formalized and
acknowledged as an official part of the health care system.
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OBJECTIVES: The elderly have accounted for more than 10% of the population in
Taiwan. It is unknown about the impact of hypertension (HTN) on the quality of life
and cognitive functions among the elderly in Taiwan. This study was initiated to
explore the elderly self-reported health statuses among the hypertensive elderly
population. METHODS: We utilized the data obtained from the 2005 National
Health Interview Survey (NHIS) in Taiwan. The study subjects contain those who
reported to have the diagnosis of HTNamong a total of 2727 elderly individuals (i.e.,
age ea65 years). The descriptive analysis with sampling weights was applied on
data including basic demographics, self-reported health status, and health care
utilization. RESULTS:While 42.8% of the survey participants reported to have HTN
(accounted for 907,062 Taiwanese elderly), 89% of them were prescribed with an-
tihypertensive agents, 85% tookmedications regularly, 21% perceived poor control
of HTN. Up to 25% of them had other co-morbidities (e.g., DM), 24% had fall events,
up to 14% had somewhat difficulties on general activities of daily living, and up to
48% had difficulties on the instrumental activities. For the past one year, up to 23%
of them had visited the inpatient and emergency departments, and less than 5%
had utilized long term care services. While 2 to 19% of them had always perceived
to have bad mood, 4 to 25% reported to take sedatives, hypnotics, painkillers, and
dietary supplements, and 31% did not receive any free elderly health check in
Taiwan. CONCLUSIONS: With approximately 40% of the elderly population per-
ceived to have hypertension, substantial portion of them were warranted for their
elderly care regarding health and functional statuses, and medication use for HTN
and for central nerves systems. Further exploration of the associations between
HTN control and health statuses for the elderly is needed.
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OBJECTIVES: To examine the health-related quality of life (HRQoL) and associated
factors in Chinese patients with stable angina pectoris (SAP), in comparison with
those of the general population.METHODS:A cross sectional HRQoL survey of both
SAP patients recruited from general hospitals (n411) and the general population
recruited from Physical Examination Centers (n549) was conducted from July to
December, 2011 in Tianjin and Chengdu cities. The general health status was as-
sessed using EQ-5D, EQ-VAS, and SF-6D instruments. SAP-specific health status
was assessed using the Seattle Angina Questionnaire (SAQ). Socio-demographic,
clinical and life style information were also collected from the participants. Hier-
archical multiple regression analyses were carried out to explore the associated
factors of HRQoL of SAP patients, in which clinical characters including SAP-spe-
cific health status, socio-demographic data and life style variables were included
via stepwise method. RESULTS: Compared with the general population ( 44.2
/10 years, 49.91% females), SAP patients (68.1/12 years, 50.36% females) had
significantly lower HRQoL scores in EQ-5D index (0.75/0.19 vs. 0.90/0.20,
p0.05), SF-6D utility index (0.68/0,12 vs. 0.85/0.11, p0.05) and EQ-VAS
(71.2/12.3 vs. 83.9/10.9, p0.05). The differences after controlling for demo-
graphic characteristics were -0.050 for EQ-5D, -9.3 for EQ-VAS and -0.133 for SF-6D.
SAQ scores showed that the patients experienced impaired disease-specific health
status, especially in the dimension of angina stability (40.5/34.6). Hierarchical
multiple linear regression analyses indicated SAP-specific health status explained
most of the variance, in which, disease perception, physical limitation and angina
stability were the strongest predictive variables for HRQoL. Among other control
variables, more exercises and better sleep were positively related with better
HRQoL. CONCLUSIONS: SAP patients experienced poorer HRQoL with lower health
utility scores compared with the general population. Enhancing disease education
and good life habits are helpful to improve the HRQoL of SAP patients.
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OBJECTIVES: To assess the correlation among Pre-operative Condition, Waiting
Time and Post-operative Outcome (mortality and morbidity) in Elective Patients
registered in the waiting list of CABG cases in Harapan Kita Hospital 2011.
METHODS: The study used quantitative method with retrospective design, com-
bined by qualitative method by doing indepth interview, observation and docu-
ment review. Samples for quantitative method are those who experienced CABG
since January until September 2011 (252 patients), and the operations were not
categorized as the emergency ones. RESULTS: The study results showed that out of
4 pre-operative conditions, only stenosis left main which has significant correlation
withwaiting time. The composit of overall risk-score had no significant correlation
with both waiting time and post-operative outcome (mortality and morbidity). In
addition, there is no significant correlation between waiting time and outcome.
This study also found that there is no waiting time management system which is
based on the patients’ pre-operative condition. Other findings are: lack of operating
room, lack of beds in ICU, limited heart surgeons, to many patients register for
CABG in this hospital, and individual system (not teamwork system) which is ap-
plied in managing the surgeons. These findings lead to quite long waiting time (25
days) for CABG patients to be operated. CONCLUSIONS: This study suggests to
Heart Surgery Unit to combine between individual and teamwork or collective
system, to develop information system which is based on patients’ pre-operative
conditions in determining schedule of surgery/operation. Suggestion also goes to
Hospital Director, in order to increase the number of operating rooms, beds in ICU,
heart surgeons, nurses. Finally this study suggest to the Ministry of Health to de-
velop or build capacity of several other hospitals located in Jakarta or outside
Jakarta to become heart centers.
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OBJECTIVES: To validate and compare the psychometric properties of two generic
preference-based HRQoL instruments, EuroQol (EQ-5D) and Short-Form 6D (SF-6D)
among stable angina pectoris (SAP) patients in China. METHODS: Validity of the
EQ-5D and SF-6D was examined with eight a priori hypotheses from a consecutive
sample (n411, mean age 68.1/11.3) of SAP patients in conjunction with Seattle
Angina Questionnaire (SAQ). Responsiveness was tested using the effect size (ES),
relative efficiency (RE) and receiver operating characteristic (ROC) curves. Agree-
ment between EQ-5D and SF-6Dwas tested using intra-class correlation coefficient
(ICC) and Bland-Altman plot. Factors affecting utility differencewere exploredwith
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